What are the latest advances in Hereditary Hemorrhagic Telangiectasia?

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is currently seeing a significant shift toward precision medicine, with recent research focusing on targeted systemic therapies to reduce bleeding and improve vascular stability. While curative gene therapies remain in early-stage development, clinical trials are actively investigating the use of anti-angiogenic agents and monoclonal antibodies to manage the complex vascular malformations associated with the condition.

What are the most promising research directions for HHT?

The primary focus of current Hereditary Hemorrhagic Telangiectasia research is to move beyond symptomatic management—such as iron supplementation or cauterization—toward targeted therapies that correct the underlying pathway dysregulation. Research is heavily centered on the TGF-β (Transforming Growth Factor-beta) signaling pathway, which is disrupted in patients with Hereditary Hemorrhagic Telangiectasia due to mutations in genes such as ENG (endoglin) or ACVRL1. Scientists are exploring how to restore balance to this pathway to prevent the formation of arteriovenous malformations (AVMs) and telangiectasias, which are the hallmark vascular lesions of the disease.

What are the latest breakthrough discoveries and clinical trials?

Recent clinical efforts have centered on repurposing existing medications to treat Hereditary Hemorrhagic Telangiectasia patients. A major breakthrough in recent years has been the investigation of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). Studies have shown that intravenous bevacizumab can significantly reduce the frequency and severity of epistaxis (nosebleeds) and improve quality of life for patients with high-output cardiac shunting. Furthermore, ongoing clinical trials are evaluating the efficacy of other agents, including:

• Pomalidomide: An immunomodulatory drug being studied for its potential to stabilize blood vessels and reduce bleeding frequency.


• Sirolimus (Rapamycin): Investigated for its ability to modulate the mTOR pathway, which may influence vascular growth in Hereditary Hemorrhagic Telangiectasia.


• Anti-fibrinolytic therapy: Ongoing assessments of systemic agents to manage acute hemorrhage.

Are there new diagnostic tools being developed?

Early detection remains vital for managing Hereditary Hemorrhagic Telangiectasia, particularly in screening for asymptomatic pulmonary AVMs. Advances in non-invasive imaging, such as contrast-enhanced echocardiography and specialized high-resolution CT protocols, are helping clinicians identify vascular malformations earlier. Additionally, researchers are investigating circulating biomarkers, such as GDF15, which may eventually help track disease severity and response to therapy in patients living with Hereditary Hemorrhagic Telangiectasia.

Which organizations are leading HHT research?

Global collaboration is accelerating the pace of discovery. The Hereditary Hemorrhagic Telangiectasia Foundation (Cure HHT) plays a pivotal role in funding research and establishing Centers of Excellence worldwide. These centers, often affiliated with major academic medical institutions, serve as hubs for both clinical care and patient-centered research, ensuring that the 141 community members on DiseaseMaps.org and others worldwide have access to the most recent clinical data.

Next steps

• Consult with a specialist at an HHT Center of Excellence to discuss whether you are a candidate for current clinical trials.


• Visit ClinicalTrials.gov and search specifically for "Hereditary Hemorrhagic Telangiectasia" to view active, recruiting studies.


• Join the DiseaseMaps.org community to share experiences and stay updated on local research initiatives.


• Discuss with your genetic counselor regarding family screening, as Hereditary Hemorrhagic Telangiectasia follows an autosomal dominant inheritance pattern.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider for diagnosis and treatment.

References

• Cure HHT (CureHHT.org) - Clinical Research and Patient Resources.


• NIH Genetic and Rare Diseases (GARD) Information Center - HHT Overview.


• Orphanet (ORPHA807) - Hereditary Hemorrhagic Telangiectasia.


• ClinicalTrials.gov - Registry of federally and privately supported clinical trials.